Table 4.
Variable | N | Univariate odds ratioa |
95% confidence interval | p-value | Multivariable odds ratio |
95% confidence interval | p-value |
---|---|---|---|---|---|---|---|
Any new or persistent symptom | 79 | 0.85 | 0.30, 2.43 | 0.76 | |||
Total family impact module score | 74 | 1.02 | 0.99, 1.04 | 0.17 | |||
Hospital length of stay | 79 | 1.05 | 0.95, 1.16 | 0.33 | |||
Sex | 79 | 0.56 | 0.21, 1.50 | 0.25 | |||
Age | 78 | 0.93 | 0.85, 1.02 | 0.11 | |||
Race | 77 | 0.60 | 0.33, 1.08 | 0.09 | |||
Ethnicity | 66 | 1.24 | 0.23, 6.79 | 0.80 | |||
Neurologic comorbidity | 79 | 0.996 | 0.34, 2.86 | 1.00 | |||
Non-neurologic comorbidity | 77 | 1.62 | 0.54, 4.80 | 0.39 | |||
Any comorbidity | 79 | 2.10 | 0.78, 5.70 | 0.14 | |||
Glasgow coma scale score, initial | 67 | 0.96 | 0.76, 1.20 | 0.71 | |||
Pediatric index of mortality | 35 | 0.95 | 0.86, 1.05 | 0.30 | |||
Pediatric logistic organ dysfunction score | 35 | 0.96 | 0.87, 1.06 | 0.43 | |||
Cerebrospinal fluid: white blood cell count | 7 | 1.01 | 0.93, 1.10 | 0.80 | |||
Sodium | 71 | 1.04 | 0.91, 1.20 | 0.54 | |||
Hemoglobin | 68 | 1.03 | 0.81, 1.32 | 0.81 | |||
C-reactive protein | 47 | 0.92 | 0.86, 0.99 | 0.02 | 0.93 | 0.86, 0.99 | 0.03 |
Ferritin | 37 | 0.9996 | 0.998, 1.00 | 0.60 | |||
Procalcitonin | 27 | 0.99 | 0.93, 1.05 | 0.64 | |||
Fibrinogenb | 31 | 0.995 | 0.99, 1.00 | 0.07 | |||
Alanine transaminase | 57 | 1.00 | 0.997, 1.00 | 0.68 | |||
Aspartate transaminase | 53 | 1.00 | 0.995, 1.01 | 0.71 | |||
Prothrombin | 31 | 1.23 | 0.88, 1.72 | 0.23 | |||
Partial thromboplastin time | 37 | 1.00 | 0.96, 1.05 | 0.95 | |||
International normalized ratio | 37 | 2.21 | 0.05, 90.08 | 0.68 | |||
D-dimer | 32 | 1.00 | 0.72, 1.40 | 0.99 | |||
Steroids | 79 | 0.39 | 0.14, 1.10 | 0.08 | |||
Remdesivir | 79 | 0.91 | 0.25, 3.31 | 0.89 | |||
Intravenous immune globulin | 79 | 0.44 | 0.14, 1.37 | 0.16 | |||
Any treatment | 79 | 0.44 | 0.16, 1.19 | 0.11 | |||
Epoch | 79 | 0.92 | 0.43, 2.00 | 0.84 | |||
COVID vs. MIS-C | 79 | 0.50 | 0.16, 1.52 | 0.22 | |||
Any neuromanifestation | 79 | 0.83 | 0.31, 2.19 | 0.70 | |||
Severe neuromanifestation | 79 | 0.996 | 0.35, 2.86 | 1.00 | |||
White blood cells | 68 | 1.00 | 0.9999, 1.00 | 0.64 | |||
Lymphocytes | 65 | 1.0005 | 0.9999, 1.001 | 0.05 | 1.001 | 1.0001, 1.002 | 0.03 |
Platelets | 67 | 1.00 | 0.999, 1.000 | 0.88 | |||
Impairmentc | 77 | 2.34 | 0.27, 21.22 | 0.43 | |||
Intensive care unit vs. ward | 79 | 1.98 | 0.68, 5.77 | 0.21 | |||
Coronavirus impact scale score | 73 | 0.88 | 0.78, 0.99 | 0.03 | 0.86 | 0.71, 1.04 | 0.12 |
Variables considered for inclusion if univariate p < 0.1.
Variable not included in multivariate due to missing >50%.
New impairment at hospital discharge was defined as any baseline to hospital discharge worsening in either the Pediatric Cerebral Performance Category (PCPC) or Functional Status Scale (FSS) score, or discharge PCPC > 1 or FSS > 6.MIS-C, multisystem inflammatory syndrome in children.